<DOC>
	<DOCNO>NCT02035540</DOCNO>
	<brief_summary>This prospective , non-randomized , single-arm , multicentre surveillance study conduct Europe . The Surveillance design study , - ESPOIR PV ( pulmonary valve ) prescribe usual manner accordance term approval . - The assignment patient particular therapeutic strategy decide advance Surveillance Protocol fall within current practice prescription ESPOIR PV clearly separate decision include patient Surveillance . - No additional diagnostic monitoring procedure shall apply patient - epidemiological method shall use analysis collect data . Evaluation decellularized human heart valve pulmonary heart valve replacement comparison current valve substitute . Safety endpoint include cardiovascular adverse event , time re-operation , re-intervention explantation . Efficacy endpoint include freedom valve dysfunction hemodynamic performance .</brief_summary>
	<brief_title>European Clinical Study Application Regenerative Heart Valves - ESPOIR</brief_title>
	<detailed_description />
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>Indication pulmonary valve replacement accord current medical guideline heart disease . Signed Informed consent legal guardian patient , assent patient . The patient provide Surveillance inform consent . The patient shall suffer generalized connective tissue disorder ( eg , Marfan syndrome ) , active rheumatic disorder , severe asymmetric calcification valve ring . The coronary artery patient shall abnormal position heavily calcify . Patients shall show hypersensitivity Sodium Dodecyl Sulphate ( SDS ) , Sodium Desoxycholate ( SDC ) , human collagen ( elastic fiber ) BenzonaseÂ® .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>